Search
D2C7 immunotoxin
go.drugbank.com/drugs/DB17540InvestigationalD2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas). … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.
Ethanolamine
go.drugbank.com/drugs/DB03994InvestigationalA viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin.
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedThe protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex.
Batroxobin
go.drugbank.com/drugs/DB09005InvestigationalIn addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. … Recombinant Batroxobin in relatively affordable and could be accessed by mass production.
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalAs of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalPGX-100 is an intravenous dosage form of modified heparin.
Managlinat dialanetil
go.drugbank.com/drugs/DB05518InvestigationalCS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
IDM-4
go.drugbank.com/drugs/DB05438ExperimentalIDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.